DyoDelta Biosciences
DyoDelta Biosciences Ltd., is a London based company specializing in deals in the Pharma / Biotech sector. We provide best-practice in corporate transactions through our management and associates. DyoDelta Biosciences is an elite group of senior executives with actual deal-making experience in the pharma and biotech industry at the corporate HQ level. We work closely with our clients/partners to put together collaborations in the life sciences.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Havas Life London
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…
Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs
MDNT
MDNT is a native Digital and Omnichannel agency focused solely on the healthcare, pharma, and life science industries. We’re highly experienced, no nonesense, and very good at what we do.
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national and international reach. As we understand the healthcare market and…
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…
Company Details
Latest Content from PMHub
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
Press Releases | October 14, 2026 | Genesis Research Group
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...
Your AI pilot works. That’s the problem.
White Papers and Resources | October 14, 2026 | 11 London
What breaks when you scale it won't be the model. It'll be your data.
“We’ve been told we can’t touch AI”
White Papers and Resources | October 14, 2026 | 11 London
It's not been a great few weeks for anyone trying to make the calm, sensible case for AI tools. Researchers have been quitting the big labs, including Anthropic, and going...
What 90 Minutes of Live AI Case Practice Revealed About Physician Readiness
Press Releases | October 12, 2026 | Medscape Education
At EHA 2026 in Stockholm, 425 hematologists and oncologists attended an independent, 90-minute Medscape symposium on the practical and ethical use of AI. The format was case-based. The faculty presented...
On GLOBE Final Rule
Press Releases | October 9, 2026 | Genesis Research Group
The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....
Rethinking Prenatal Migraine Management: The Clinical Case for Neuromodulation
Press Releases | October 8, 2026 | Medscape Education
Disclaimer: Management of migraine in pregnancy typically combines lifestyle strategies, nonpharmacologic approaches, selected pharmacologic options when benefits outweigh risks, and, increasingly, noninvasive neuromodulation technologies.
Pharma leadership strategies for talent, AI adoption, and continuous learning
White Papers and Resources | October 8, 2026 | Inizio
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...
Invited, but not equipped: patient involvement needs more than an open door
White Papers and Resources | October 8, 2026 | Cuttsy + Cuttsy
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
Advancing the Frontier of Cancer Care: Medscape’s Mission at ESMO 2026
Press Releases | October 5, 2026 | Medscape Education
For more than 30 years, Medscape Education's dedication has been centered on a single goal: building independent, accredited oncology education that improves patient outcomes. This year, at the European Society...
Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.
Press Releases | October 2, 2026 | Genesis Research Group
On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.